^
Association details:
Biomarker:MSH2 mutation
Cancer:Pancreatic Ductal Adenocarcinoma
Regimen: (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX

Published date:
10/09/2018
Excerpt:
Mutations were seen in BRCA1 (N = 7), BRCA2 (N = 5), BRCA1/2 (N = 3), PALB2 (N = 3), MSH2 (N = 1) and FANCF (N = 1) of all the DDR genes sequenced...Cox regression (HR 0.37 [0.15-0.94], p = 0.04) showed presence of DDRGM was associated with improved OS....we found that the presence of germline and somatic DDRGM as well as germline BRCA1/2 mutations are associated with improved OS in PDAC patients treated with FOLFIRINOX.
DOI:
10.1093/annonc/mdy282.100